Autoantibodies and thrombophilia in RA: TNFα and TNFα blockers

Annals of the Rheumatic Diseases

Volumn 63, Issue 6, 2004, Pages 613-615

  Ferraccioli, G F ^a   Gremese, E ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINUCLEAR ANTIBODY; AUTOANTIBODY; C REACTIVE PROTEIN; CARDIOLIPIN ANTIBODY; DNA ANTIBODY; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ETANERCEPT; INFLIXIMAB; INTERLEUKIN 1BETA; LIPOPROTEIN LIPASE; LOW DENSITY LIPOPROTEIN RECEPTOR RELATED PROTEIN; LUPUS ANTICOAGULANT; PHOSPHOLIPID ANTIBODY; PLACEBO; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RHEUMATOID FACTOR; SCAVENGER RECEPTOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ATHEROGENESIS; ATHEROSCLEROSIS; AUTOIMMUNITY; CARDIOTOXICITY; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORRELATION ANALYSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DISEASE CONTROL; DISEASE COURSE; DISEASE EXACERBATION; DISEASE PREDISPOSITION; DRUG CONTRAINDICATION; DRUG EFFICACY; DRUG PACKAGING; FEMUR HEAD NECROSIS; GENE EXPRESSION REGULATION; HEART FAILURE; HEART INFARCTION; HEART MUSCLE ISCHEMIA; HUMAN; INFLAMMATION; MEDIATOR; MYOCARDIAL DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OSTEOARTHRITIS; PRIORITY JOURNAL; PROTEIN FUNCTION; RHEUMATOID ARTHRITIS; RISK FACTOR; SHORT SURVEY; THROMBOPHILIA; VASCULAR DISEASE;

ARTHRITIS, RHEUMATOID; AUTOANTIBODIES; CARDIOVASCULAR DISEASES; FEMALE; HUMANS; INTERLEUKIN-1; RISK FACTORS; THROMBOPHILIA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 2442656763     PISSN: 00034967     EISSN: None     Source Type: Journal    
DOI: 10.1136/ard.2003.015586     Document Type: Short Survey

References (46)

1. Wolfe F, Mitchell DM, Sibley JT, Fries JF, Bloch DA, Williams CA, et al. The mortality of rheumatoid arthritis. Arthritis Rheum 1994;37:481-94.
2. Solomon DH, Karlson EW, Rimm EB, Cannuscio CC, Mandl LA, Manosn JE, et al. Cardiovascular morbidity and mortality in women diagnosed with rheumatoid arthritis. Circulation 2003;107:1303-7.
3. Del Rincon I, Williams K, Stern MP, Freeman GL, Escalante A. High incidence of cardiovascular events in a rheumatoid arthritis cohort not explained by traditional cardiac risk factors. Arthritis Rheum 2001;44:2737-45.
4. Alkaabi JK, Ho M, Levison R, Pullar T, Belch JJF. Rheumatoid arthritis and macrovascular disease. Rheumatology (Oxford) 2003;42:292-7.
5. Michaud K, Mendelsohn AM, Wolfe F. Congestive heart failure in RA: rates, predictors and the effect of anti-TNF therapy. Ann Rheum Dis 2003;62(suppl 1):S99.
6. Laakso M. Cardiovascular disease in type 2 diabetes: challenge for treatment and prevention. J Intern Med 2001;249:225-35.
7. Engstrom G, Stavenov L, Hedblad B, Lind P, Eriksson KF, Janzon I, et al. Inflammation-sensitive plasma proteins, diabetes, and mortality and incidence of myocardial infarction and stroke: population-based study. Diabetes 2003;52:442-7.
8. Ross R. Atherosclerosis, an inflammatory disease. N Engl J Med 1999;340:115-25.
9. Libby P. Inflammation in atherosclerosis. Nature 2002;420:868-74.
10. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Ann Rev Immunol 1996;14:397-40.
11. Arend WP, Dayer JM. Inhibition of the production and effects of interleukin 1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
12. Beutler B, Mahoney J, Le Trang N, Pekala P, Cerami A. Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin induced RAW 264.7 cells. J Exp Med 1985;161:984-95.
13. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? the mouse's tale. J Clin Invest 2001;108:649-54.
14. Devaraj S, Xu DY, Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells. Implications for the metabolic syndrome and atherothrombosis. Circulation 2003;107:398-404.
15. Shimaoka T, Kume N, Hayashida K, Sawamura T, Kita T, Yonehara S. LOX-1 supports adhesion of gram-positive and gram-negative bacteria. J Immunol 2001;166:5108-14.
16. Anderson HD, Rahmutula D, Gardner DG. Tumor necrosis factor-alpha inhibits endothelial nitric oxide synthase gene promoter activity in bovine aortic endothelial cells. J Biol Chem 2004;279:963-9.
17. Neumann P, Gertzberg N, Johnson A. TNF alpha induces a decrease in eNOS-promoter activity. Am J Physiol Lung Cell Mol Physiol 2004;286:452-9.
18. Honjo M, Nakamura K, Yamashiro K, Kiryu J, Tanihara H, McEvoy LM, et al. Lectin like oxidized LDL receptor-1 is a cell-adhesion molecule involved in endotoxin-induced inflammation. Proc Natl Acad Sci USA 2003;100:1274-9.
19. Nagase M, Abe J, Takahashi K, Ando J, Hirose S, Fujita T. Genomic organization and regulation of expression of the lectin-like oxidized low density lipoprotein receptor (LOX-1) gene. J Biol Chem 1998;273:33702-7.
20. Ley K, Huo Y. VCAM-1 is critical in atherosclerosis. J Clin Invest 2001;107:1209-10.
21. Dewberry R, Holden H, Crossman D, Francis S. Interleukin-1 receptor antagonist expression in human endothelial cells and atherosclerosis. Arterioscl Thromb Vasc Biol 2000;20:2394-400.
22. Wong ML, Xie B, Beatini N, Phu P, Marathe S, Johns A, et al. Acute systemic inflammation up-regulates sphingomyelinase in vivo: a possible link between inflammatory cytokines and atherogenesis. Proc Natl Acad Sci USA 2000;97:8681-6.
23. Cambien B, Bergmeier W, Saffaripour S, Mitchell HA, Wagner DD. Antithrombotic activity of TNF-α. J Clin Invest 2003;112:1589-96.
24. Macik BG, Rand JH, Konkle BA. Thrombophilia: what's a practitioner to do? Hematology 2001:322-38.
25. Merkel PA, Chang Y, Pierangeli SS, Convery K, Harris EN, Polisson RP. The prevalence and clinical associations of anticardiolipin antibodies in a large inception cohort of patients with connective tissue diseases. Am J Med 1996;101:576-83.
26. Seriolo B, Fasciolo D, Sulli A, Cutolo M. Homocysteine and anticardiolipin antibodies in rheumatoid arthritis patients: relationships with thrombotic events. Clin Exp Rheumatol 2001;19:561-4.
27. Vittecoq O, Jouen-Beades F, Krzanowska K, Bichon-tauvel I, Menard JF, Daragon A, et al. Prospective evaluation of the frequency and clinical significance of antineutrophil cytoplasmic anticardiolipin antibodies in community cases of patients with rheumatoid arthritis. Rheumatology (Oxford) 2000;39:481-9.
28. Bonnet C, Vergne P, Bertin P, Treves R, Jauberteau MO. Antiphospholipid antibodies and RA: presence of β2GPI independent aCL. Ann Rheum Dis 2001;60:303-4.
29. Galli M, Luciani D, Beryolini G, Barbui T. Lupus anticoagulants are stronger risk factors for thrombosis than anti-cardiolipin antibodies in the antiphospholipid syndrome: a systematic review of the literature. Blood 2003;101:1827-32.
30. Hurlimann D, Forster A, Noll G, Enseleit F, Chenevard R, Distler O, et al. Anti-tumor necrosis factor α treatment improves endothelial function in patients with RA. Circulation 2002;106:2184-7.
31. Hansel S, Lassig G, Pistrosch F, Passauer J. Endothelial dysfunction in young patients with long-term rheumatoid arthritis and low disease activity. Atherosclerosis 2003;170:177-80.
32. Ferraccioli GF, Mecchia F, Di Poi E, Fabris M. Anticardiolipin antibodies in rheumatoid patients treated with etanercept or conventional combination therapy: direct and indirect evidence for a possible associations with infections. Ann Rheum Dis 2002;61:358-61.
33. Ferraccioli GF, Assaloni R, Di Poi E, Gremese E, De Marchi G, Fabris M. Rescue of combination therapy failures using infliximab, while maintaining combination or the monotherapy with methotrexate: results of an open trial. Rheumatology (Oxford) 2002;41:1109-12.
34. Weinblatt ME, Kremer JM, Bankhurst AD, Bulpitt KJ, Fleishmann RM, Fox RI, et al. A trial of etanercept, a recombinant tumor necrosis factor receptor: Fc fusion protein, in patients with rheumatoid arthritis receiving methotrexate. N Engl J Med 1999;340:253-9.
35. Lipsky PE, Van der Heijde DMFM, St Clair EW, Furst DE, Breedveld FC, Kalden JR, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000;343:1594-602.
36. Kwon HJ, Cote' TR, Cuffe MS, Kramer JM, Braun MM. Case report of heart failure after therapy with a tumor necrosis factor antagonist. Ann Intern Med 2003;138:807-11.
37. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT for the ATTACH trial. Randomized double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor alpha, in patients with moderate-to severe heart failure. Results of the anti-TNF therapy against congestive heart failure (ATTACH) trial. Circulation 2003;107:3133-40.
38. Mann DL, McMurray JJ. Presentation of the results of the RENAISSANCE, RECOVER and RENEWAL studies. Heart Failure 2002, Meeting. Oslo, Norway, 8-11 June 2002.
39. Paul E, Carroll M. SAP-less chromatin triggers systemic lupus erythematosus. Nature Med 1999;5:607-8.
40. Bickerstaff MCM, Botto M, Hutchinson WL, Herbert J, Tennent GA, Bybee A, et al. Serum amyloid P component controls chromatin degradation and prevents antinuclear autoimmunity. Nature Med 1999;5:694-7.
41. Thompson D, Pepys MB, Wood SP. The physiological structure of human C reactive protein and its complex with phosphocholine. Structure 1999;7:169-77.
42. Pepys MB, Booth SE, Tennent GA, Butler PJG, Williams DG. Binding of pentraxins to different nuclear structures: C-reactive protein binds to small nuclear ribonucleoprotein particles, serum amyloid P component binds to cnromatin and nucleoli. Clin Exp Immunol 1994;97:152-7.
43. Via CS, Shustov A, Rus V, Lang T, Nguyen P, Finkelman FD. In vivo neutralization of TNFα promotes humoral autoimmunity by preventing the induction of CTL. J Immunol 2001;167:6821-6.
44. Shustov A, Luzina I, Nguyen P, Papadimitriou JC, Handwerger B, Elkon KB, et al. Role of perforin in controlling B-cell hyperactivity and humoral autoimmunity. J Clin Invest 2000;106:39-47.
45. Blank M, Krause I, Fridkin M, Keller N, Kopolovic J, Goldberg I, et al. Bacterial induction of autoantibodies to β2glycoprotein I accounts for the infectious etiology of antiphospholipid syndrome. J Clin Invest 2002;109:797-804.
46. Shoenfeld Y, Sherer Y. Atherosclerosis. Ann Rheum Dis 2002;61:97-9.